Geron 2025 Q3 Earnings 30.3% Net Loss Reduction Amid Strong Revenue Growth

Geron (GERN) reported fiscal 2025 Q3 earnings on Nov 8, 2025, with revenue rising 67.1% to $47.23 million, exceeding prior-year results but falling short of analyst expectations. The company narrowed its net loss to $18.43 million (30.3% improvement) and achieved an EPS of -$0.03, matching guidance. Analysts highlighted optimism around RYTELO’s market potential and 2026 EU commercialization plans, though mixed demand and cost discipline remain key focus areas.

Revenue

, driven primarily by product revenue, . , reflecting the company’s diversified revenue streams. This growth was fueled by increased demand for RYTELO, particularly in first- and second-line treatments, .

Earnings/Net Income

, a 30.3% improvement from the $26.45 million loss in the prior-year period. The EPS narrowed to -$0.03 from -$0.04, representing a 25% improvement. While the loss remains significant, the reduction signals progress in cost management and operational efficiency.

Post-Earnings Price Action Review

Following the earnings release, Geron’s stock price showed mixed performance. Despite the revenue outperformance and narrower losses, . This volatility underscores investor caution, balancing optimism over RYTELO’s growth potential against concerns about demand sustainability and operational challenges.

CEO Commentary

, CEO, emphasized RYTELO’s differentiation in the MDS treatment landscape, . However, , attributing this to the need for deeper physician education on early-line adoption. Semerjian highlighted preparations for EU commercialization in 2026, including the first shipment of RYTELO to Germany under an early access program, and reiterated confidence in the drug’s long-term market potential.

Guidance

Management refrained from providing explicit 2026 revenue guidance but signaled a focus on cost discipline, . Semerjian described 2026 as a “growth story,” emphasizing execution on commercial initiatives and physician education as key drivers for future revenue expansion.

Additional News

Geron announced strategic moves to expand RYTELO’s commercial footprint into select EU markets by 2026, with appointed as Chief Commercial Officer to lead efforts. , 2025, . Additionally, the IMpactMF Phase III trial for imetelstat in myelofibrosis is fully enrolled, with interim results expected in late 2026. These developments underscore Geron’s dual focus on near-term cost control and long-term pipeline milestones.